GlassScriptPhysician profile
Kathleen Webb Mackey
NPI 1932104999
$3,017.72
in general payments reported to CMS, 2019-2025
37 companies · $1,385 in 2025
The $1,385 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $140 · 2022: $346 · 2023: $257 · 2024: $890 · 2025: $1,385.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,488 · Education: $43.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,488.29 |
| Education | $43.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $459.93 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $276.09 | 2022-2025 | Enhertu, Calquence, Lynparza |
| Pfizer INC. | $199.01 | 2022-2025 | |
| Daiichi Sankyo INC. | $176.98 | 2022-2025 | Enhertu, Injectafer, Vanflyta |
| Merck Sharp & Dohme LLC | $164.28 | 2023-2025 | Keytruda, Welireg, Keytruda Qlex |
| Eisai INC. | $156.04 | 2022-2025 | |
| Incyte Corporation | $130.06 | 2023-2025 | Jakafi, Monjuvi, Zynyz |
| Novartis Pharmaceuticals Corporation | $127.34 | 2023-2025 | |
| Ipsen Biopharmaceuticals, INC | $125.66 | 2021-2024 | Onivyde |
| Takeda Pharmaceuticals U.S.A., INC. | $111.86 | 2024-2025 | Ninlaro, Fruzaqla |
| Exelixis INC. | $74.97 | 2022-2025 | Cabometyx |
| Bayer Healthcare Pharmaceuticals INC. | $73.02 | 2024-2025 | |
| Celgene Corporation | $68.78 | 2022-2025 | Reblozyl |
| Seagen INC. | $68.60 | 2022-2023 | Adcetris |
| Gilead Sciences, INC. | $68.10 | 2024-2025 | Trodelvy |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $67.90 | 2022-2024 | Opdivo |
| Glaxosmithkline, LLC. | $66.88 | 2022-2024 | Ojjaara |
| Janssen Biotech, INC. | $62.41 | 2024-2025 | Rybrevant, Darzalex |
| Genentech USA, INC. | $58.69 | 2023-2025 | Polivy, Kadcyla, Phesgo |
| Beone Medicines USA, INC. | $48.44 | 2025 | Tevimbra, Brukinsa |
| Pharmacyclics LLC, An Abbvie Company | $46.82 | 2022 | |
| Secura Bio, INC. | $39.28 | 2021 | |
| Alexion Pharmaceuticals, INC. | $35.97 | 2024-2025 | Ultomiris |
| Regeneron Healthcare Solutions, INC. | $28.31 | 2024 | Libtayo |
| Recordati_rare_diseases_inc. | $28.22 | 2025 | Enjaymo |
| Spectrum Pharmaceuticals INC. | $27.18 | 2025 | Rolvedon |
| Puma Biotechnology, INC. | $24.82 | 2025 | |
| Invivyd INC | $24.47 | 2025 | Pemgarda |
| Beigene USA, INC. | $21.89 | 2024 | Brukinsa |
| Genzyme Corporation | $21.76 | 2025 | |
| Dendreon Pharmaceuticals LLC | $21.71 | 2025 | Provenge |
| Sumitomo Pharma America, INC. | $21.17 | 2025 | Orgovyx |
| Nuvation Bio INC. | $19.65 | 2025 | Ibtrozi |
| Array Biopharma INC | $19.37 | 2025 | Braftovi |
| Jazz Pharmaceuticals INC. | $19.19 | 2025 | |
| Deciphera Pharmaceuticals INC. | $17.06 | 2024 | Qinlock |
| Astellas Pharma US INC | $15.81 | 2024 | Padcev |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathleen Mackey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.